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Abstract
L-Glutamate is the major excitatory neurotransmitter in the brain. Astrocytes maintain low levels of synaptic glutamate by high-affinity
uptake and defects in this function may lead to neuronal cell death by excitotoxicity. We tested the effects of HIV-1 and its envelope
glycoprotein gp120 upon glutamate uptake and expression of glutamate transporters EAAT1 and EAAT2 in fetal human astrocytes in vitro.
Astrocytes isolated from fetal tissues between 16 and 19 weeks of gestation expressed EAAT1 and EAAT2 RNA and proteins as detected
by Northern blot analysis and immunoblotting, respectively, and the cells were capable of specific glutamate uptake. Exposure of astrocytes
to HIV-1 or gp120 significantly impaired glutamate uptake by the cells, with maximum inhibition within 6 h, followed by gradual decline
during 3 days of observation. HIV-1-infected cells showed a 59% reduction in Vmax for glutamate transport, indicating a reduction in the
number of active transporter sites on the cell surface. Impaired glutamate transport after HIV-1 infection or gp120 exposure correlated with
a 40–70% decline in steady-state levels of EAAT2 RNA and protein. EAAT1 RNA and protein levels were less affected. Treatment of
astrocytes with tumor necrosis factor- (TNF-) decreased the expression of both EAAT1 and EAAT2, but neither HIV-1 nor gp120 were
found to induce TNF- production by astrocytes. These findings demonstrate that HIV-1 and gp120 induce transcriptional downmodulation
of the EAAT2 transporter gene in human astrocytes and coordinately attenuate glutamate transport by the cells. Reduction of the ability of
HIV-1-infected astrocytes to take up glutamate may contribute to the development of neurological disease.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Dementia is a major complication of HIV-1 infection and
an AIDS defining illness that until recently afflicted about a
third of AIDS patients (Lipton and Gendelman, 1995; Navia
et al., 1986; Navia and Price, 1987). The incidence of
HIV-1-associated dementia (HAD) declined after the intro-
duction of highly active antiretroviral therapies, but it still
reaches 10% (Sacktor et al., 2001). The pathological hall-
marks of HAD include neuronal loss, reactive gliosis, and
white matter pallor (Budka, 1991; Everall et al., 1991;
Navia et al., 1986; Sharer et al., 1986). HIV-1 infects infil-
trating macrophages, microglial cells, and astrocytes in the
brain (Koening et al., 1986; Ranki et al., 1995; Saito et al.,
1994) but it is rarely found in neurons (Wiley et al., 1986),
suggesting indirect viral action in neuronal cell loss. It has
been suggested that cellular and viral products made by
productively infected macrophages and microglial cells, in-
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cluding TNF-, nitric oxide, gp120, and Tat, trigger inflam-
matory and neurotoxic reactions leading to HAD (Kaul et
al., 2001; Lipton and Gendelman, 1995). Consistent with
this hypothesis, HIV-1-infected human macrophages trans-
planted into mouse brain induced histopathological damage
reminiscent of HAD (Persidsky et al., 1996). However, not
all of the neuropathogenic effects of HIV-1 can be ex-
plained by productive HIV-1 infection in the brain. HAD is
not always found in individuals with high virus burdens in
the brain and is sometimes found in persons with low
numbers of HIV-1-infected macrophages or microglial cells
(Brew et al., 1995; Glass et al., 1995). Although X4 and not
R5 virus is able to induce neuronal apoptosis in vitro (Oha-
gen et al., 1999; Zheng et al., 1999), many studies indicate
that R5 HIV-1 strains predominate in the brain, consistent
with their replication in monocytic cells (Korber et al.,
1994; Power et al., 1994, 1998). Finally, some CNS isolates
of HIV-1 poorly utilize CCR5 or preferentially replicate in
T lymphocytes or in astrocytes (Canki et al., 1997; Smit et
al., 2001). Together these findings indicate complexity in
host cell tropism and receptor utilization by CNS-derived or
neurotropic HIV-1 and in viral effects on its host cells in the
brain.
A number of laboratories including ours have investi-
gated astrocytes as targets for HIV-1 infection and pathol-
ogy in the brain (reviewed by Brack-Werner, 1999; Conant
et al., 1998). Although initially controversial (Gosztonyi et
al., 1994; Wiley, 1996; Wiley et al., 1986), HIV-1 infection
of astrocytes in vivo has been documented in many studies
(An et al., 1999; Bagasra et al., 1996; Nuovo et al., 1994;
Ranki et al., 1995; Saito et al., 1994; Stoler et al., 1986;
Takahashi et al., 1996; Tornatore et al., 1994a). We have
recently confirmed these findings by demonstration of
HIV-1 DNA in individual astrocytes isolated from autopsy
brain tissue by laser capture microdissection (Trillo-Pazos
et al., 2003). Some reports, including ours, indicate that the
frequency of HIV-1-positive astrocytes can reach about 1%
in specific regions (Takahashi et al., 1996; Trillo-Pazos et
al., 2003). The actual proportion of HIV-1-infected astro-
cytes varies by brain region analyzed and severity of CNS
disease (Saito et al., 1994; Takahashi et al., 1996; Wiley et
al., 1986) and it is higher in pediatric cases than in adults
(Saito et al., 1994; Trillo-Pazos et al., 2003). The variability
of HIV-1 detection in astrocytes in vivo likely contributes to
the differences in opinion regarding the potential role of this
infection in neuropathogenesis (Brack-Werner, 1999; Co-
nant et al., 1998; Wiley, 1996).
In vivo, HIV-1-infected astrocytes express predomi-
nantly viral regulatory genes rather than structural genes
associated with virus production (Ranki et al., 1995; Taka-
hashi et al., 1996). This, and the high prevalence of gliosis
in HAD (Budka, 1991), suggest that astrocytes survive
HIV-1 infection in vivo and may carry virus for extended
periods of time. Astrocytes engaged in apoptosis have also
been described by some investigators (Shi et al., 1996;
Thompson et al., 2001) but not by others (Hery et al., 1997;
Krajewski et al., 1997). Consistent with observations in
patients’ tissues, HIV-1 infection of astrocytes in culture is
low-productive, persistent, and noncytolytic (Cheng-Mayer
et al., 1987; Dewhurst et al., 1987; Kunsch et al., 1989; Nath
et al., 1995; Tornatore et al., 1991, 1994b) but the cells
clearly have the capacity to produce infectious progeny
virus (Canki et al., 2001; Cheng-Mayer et al., 1987; Hatch
et al., 1994). The interaction of HIV-1 or gp120 with pri-
mary human astrocytes was shown to be independent of
CD4, the viral coreceptors, and galactosyl ceramide
(Cheng-Mayer et al., 1987; Ma et al., 1994; Sabri et al.,
1999) and it may be mediated by an unknown high-affinity
receptor for gp120 (Ma et al., 1994). HIV-1 replication in
astrocytes can be increased by treatment with TNF- and
other cytokines (Canki et al., 2001; Shahabuddin et al.,
1992a; Tornatore et al., 1991), indicating responses to phys-
iological stimuli similar to those observed in other HIV-1
host cells (Rosenberg and Fauci, 1989). In summary, human
astrocytes have emerged as an abundant and potentially
important target cell for HIV-1 in the brain, but one in
which the characteristics of HIV-1 infection are very dif-
ferent from the highly productive interaction typical for
T-lymphocytes, macrophages, and microglial cells.
The present work was designed to address the cellular
aspects of this atypical virus–cell interaction to determine
the consequences of HIV-1 infection upon astrocyte func-
tions. These essential functions include maintaining brain
homeostasis, regulating the levels of extracellular gluta-
mate, serving as a component of the blood-brain barrier, and
responding to pathogens and brain injury (Danbolt, 2001;
Dong and Benveniste, 2001; Verkhratsky et al., 1998). Re-
cent research also suggests that astrocytes play a critical role
in neuronal signal transmission by enhancing synaptic ac-
tivity and strength, increasing the number of synapses, and
modulating neuronal activity (Beattie et al., 2002; Iino et al.,
2001; Oliet et al., 2001; Ullian et al., 2001). Disruption of
any of these functions by HIV-1 could have significant
impact on the progression of HIV-1 disease in the brain. We
began to investigate the effect of HIV-1 and gp120 upon
Na-coupled transport of L-glutamate and the expression of
glutamate transporters mediating this uptake in primary
human astrocytes. Five glutamate transporters (EAAT1–5)
have so far been identified in humans; of these, EAAT1 and
EAAT2 are expressed predominantly in astrocytes in the
CNS and are believed to mediate most glutamate uptake in
the brain (Anderson and Swanson, 2000; Danbolt, 2001;
Gegelashvili and Schousboe, 1997; Palacin et al., 1998;
Robinson, 1999). Here we show that exposure of human
fetal astrocytes to HIV-1 or gp120 in culture induces tran-
scriptional downmodulation of the glial glutamate trans-
porter EAAT2 and reduction in expression of EAAT2 pro-
tein, resulting in extensive and lasting disruption of
glutamate uptake by astrocytes.
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Results
Human fetal astrocytes express EAAT1 and EAAT2
transcripts and proteins and exhibit specific, high-affinity
glutamate transport activity
Although HAD is a postnatal disease, fetal brain is the
only practical source of primary human astrocytes in the
numbers needed for experimental HIV-1 infection and bio-
chemical and molecular studies. On that basis we adopted
human fetal astrocytes as a model for this research. Astro-
cyte cultures were established from abortus brain tissue by
a previously described procedure that permits isolation of an
essentially homogeneous population of astrocytes (Ben-
cheikh et al., 1999; Zheng et al., 1999). Fig. 1 shows
photomicrographs from a typical culture used in the present
studies after staining cells for expression of GFAP, the
canonical astrocyte marker; HAM-56, a marker expressed
by monocytic cells including microglial cells; and HLA-
DR, which is expressed by both cell types after activation.
Essentially all cells in culture expressed high levels of
GFAP and HLA-DR, but no detectable HAM-56, indicating
that they consisted mostly of astrocytes. There was no
detectable nonspecific staining (Fig. 1D). Batches of astro-
cytes were routinely monitored for expression of these an-
tigens with similar results.
Next we confirmed that fetal astrocytes express the two
known glial glutamate transporters EAAT1 (GLAST) and
EAAT2 (GLT-1) and tested whether the cells are capable of
specific glutamate transport. Fig. 2 shows the results of
EAAT protein and RNA analyses in astrocytes. All cell
extracts were standardized for expression of a housekeeping
protein, -tubulin, or a housekeeping RNA, ribosomal small
subunit protein 9 (RPS), prior to evaluation of transporter
expression (Fig. 2). Since expression of glutamate transport-
ers is developmentally regulated (Bar-Peled et al., 1997;
Shibata, 1997), initial experiments determined the presence
of EAAT2 in cells of different gestational age (Fig. 2A). We
found that astrocytes expressed the EAAT2 protein of the
expected approximate mass of 73–75 kDa and that EAAT2
expression increased between 16 and 19 weeks of gestation
(Fig. 2A), consistent with the observed changes in trans-
porter expression during development (Bar-Peled et al.,
1997). Further studies described here employed cells of 16
weeks or greater gestational age. We also compared two
different batches of astrocytes (18 weeks gestation time) for
expression of EAAT1 and EAAT2 and found that EAAT2
was more readily detectable than EAAT1 (Fig. 2B). The
difference is probably due to different sensitivities of anti-
EAAT1 and EAAT2 antibodies, as EAAT1 is known to be
expressed well by prenatal astrocytes (Bar-Peled et al.,
1997). To confirm these studies at the RNA level, we
performed Northern blot analysis using RNA extracted from
three further astrocyte populations (Fig. 2C). Both the 4-kb
EAAT1 and the 12-kb EAAT2 RNA (Arriza et al., 1994)
were detectable in cells from three different donors. The
glioma cell line U87 did not produce detectable EAAT2
RNA but, consistent with previous reports (Ye et al., 1999),
expressed low levels of EAAT1 RNA.
To determine whether astrocytes are capable of specific
glutamate transport, we employed the assay of L-[3H]-glu-
tamate uptake, essentially as previously described (Fine et
al., 1996). We first determined the time course and speci-
ficity of L-[3H]-glutamate uptake. As shown in Fig. 3, as-
trocytes internalized glutamate linearly with time up to 15
min after exposure. Further assays were performed within
this linear phase of uptake. The specificity of the assay was
demonstrated by inhibition of glutamate uptake in the pres-
ence of 250-fold excess of unlabeled EAAT1/EAAT2 li-
gands L-glutamate or L-aspartate, or after preincubation with
a conformationally constrained substrate analog L-trans-2,4-
PDC (inset in Fig. 3). Similar results were obtained in five
experiments with different astrocyte preparations. Analysis
of glutamate uptake kinetics in fetal astrocytes, similar to
that shown later in this work (Fig. 6), determined the Vmax
for transport of 4–5 nmol glutamate/mg protein/min and Km
of 19–20 M, both within the range reported for Na-
dependent, high-affinity glutamate transport in primary hu-
man and rodent astrocytes or synaptosomal vesicles (Dan-
bolt, 2001; Fine et al., 1996; Robinson, 1998). Together,
these results indicate that fetal human astrocytes express
glutamate transporters EAAT1 and EAAT2 and can be
reliably monitored for specific glutamate uptake and its
inhibition in culture.
Fig. 1. Expression of selected cellular markers by human fetal astrocytes in
culture. Astrocytes of 16 weeks gestational age were cultured on cover
slips and stained for the designated proteins as described under Materials
and methods. Control mouse immunoglobulin was used as the primary
antibody in (D).
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HIV-1 infection or exposure to gp120 attenuates
glutamate uptake by primary human astrocytes
Next we investigated the effects of HIV-1 and recombi-
nant gp120 protein on glutamate uptake by astrocytes and
on EAAT1 and EAAT2 expression. Astrocytes were ex-
posed to HIV-1/NL4-3 at 1 infectious units (IU) per cell and
virus infection was monitored by measuring the levels of
extracellular and intracellular HIV-1 p24 capsid antigen
over 10 days in culture (Fig. 4). As previously reported by
others as well as ourselves (Bencheikh et al., 1999; Canki et
al., 2001; Nath et al., 1995; Tornatore et al., 1991), and
analogous to infection observed in astrocytes in the brain
(Saito et al., 1994; Takahashi et al., 1996), infection of
astrocytes by HIV-1 was low-productive and noncytopathic,
peaking at about 50,000 pg p24 per 106 cells (Fig. 4). To
determine functional consequences of exposure, astrocytes
were tested for their ability to take up L-[H3]-glutamate at
various times after HIV-1 infection or treatment with gly-
cosylated gp120 at 1 nM. Fig. 5A and B shows typical
experiments revealing that within 6 h both HIV-1 infection
and gp120MN exposure significantly inhibited glutamate up-
take by astrocytes. At this time, the inhibition was about
70% in HIV-1-infected cells and nearly 60% in gp120-
treated cells. Inhibition declined over the course of obser-
vation, although it was still measurable 3 days after treat-
ment at 19  7% for HIV-1 and 25  8% for gp120 (Fig.
5A and B). We tested the specificity of the response and
found that X4 HIV-1/NDK and R5 HIV-1/ADA infection
also inhibited glutamate uptake by astrocytes at levels sim-
ilar to infection by NL4-3, but that exposure to serum
albumin or ovalbumin at 100-fold excess over gp120 had no
Fig. 2. Expression of glutamate transporters EAAT1 and EAAT2 by human fetal astrocytes in culture. (A) 5, 10, and 20 g protein per lane from three
populations of astrocytes at the indicated gestational ages were subjected to immunoblotting using anti-EAAT2 or anti--tubulin as described under Materials
and methods. (B) 5, 10, and 20 g protein per lane from two different populations of astrocytes of 18 weeks gestational age or 10 g protein from
negative-control CEM T lymphoblastoid cells were subjected to immunoblotting using anti-EAAT1, anti-EAAT2, or anti--tubulin as described under
Materials and methods. (C) One microgram of total RNA isolated from three different populations of astrocytes of 16–18 weeks gestational age or from
U87MG glioma cells was subjected to Northern blot analysis probing for EAAT1, EAAT2, and RPS transcripts as described under Materials and methods.
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effect upon glutamate uptake at any time (not shown). The
inhibition of glutamate uptake in astrocytes was virus and
gp120 dose-dependent, reaching maximum levels with 1 IU
of HIV-1/NL4-3 per cell and 1 nM gp120MN. To determine
the reproducibility of the observed responses, we tested a
large number of astrocyte pools for glutamate uptake after
exposure to NL4-3 or gp120MN (Fig. 5C–D). Overall, at the
doses used, infection by NL4-3 was more inhibitory than
was exposure to gp120 at their optimal doses. At the 6 h
time point, the inhibition by HIV-1 was 75.8  13.8%
(mean  SD, n  20) and gp120-mediated effect was 58.0
 17.9% (n  10) (P  0.001, paired Student’s t test). The
respective values at 24 h after treatment were 54.3 15.9%
(n  15) and 36.5  15.4% (n  10) with P  0.05.
Together, the data shown in Fig. 5 using cells from more
than 25 different brains indicate that HIV-1 and its envelope
glycoprotein have a pronounced, specific, long-lasting, and
reproducible inhibitory effect upon the ability of human
astrocytes to take up extracellular glutamate.
HIV-1-induced impairment of glutamate uptake correlates
with reduction in glutamate transport velocity (Vmax) and
downmodulation of the expression of EAAT2 protein and
RNA in primary human astrocytes
A variety of physiological and pathogenic stimuli were
shown to regulate glutamate transport at multiple levels,
including control of transcription, mRNA processing, and
translation of EAAT genes, posttranslational modifications
of EAAT proteins, or changes in the ionic or electrophysi-
ological environment of astrocytes (Danbolt, 2001;
Gegelashvili et al., 1997; Maragakis and Rothstein, 2001).
To begin to investigate the mechanism of the observed
HIV-1 and gp120 effects, we first characterized the bio-
chemical properties of glutamate transport activity to deter-
mine whether HIV-1 exposure altered transport constants
Vmax and Km (Fig. 6). Concentration-dependence of L-[3H]-
glutamate uptake was tested in HIV-1 infected and control
astrocytes; the results are shown in the insets in Fig. 6A and
B. Eadie–Hofstee transformation of these data was used to
derive transport constants (Fig. 6). HIV-1 exposure de-
creased the Vmax value from 4.6 0.4 in control cells to 1.9
 0.3 nmol/mg protein/min, a 59% decline, but had no
significant effect on the Km (19.1  2.3 M in control and
23.75  2.0 M in HIV-1-treated cells), indicating that
HIV-1 infection reduced the number of glutamate transport-
ers functional at the astrocyte surface without altering their
affinity for glutamate.
To determine whether the observed inhibition of gluta-
mate transport correlates with expression of transporter pro-
tein or RNA, we tested the steady-state expression of
EAAT1 and EAAT2 proteins by Western blot and levels of
transporters mRNA by Northern blot (Fig. 7). Astrocytes
were treated with HIV-1/NL4-3, and for comparison, with a
known inducer of EAAT2 expression 8-bromo-cyclic aden-
osine monophosphate (8-Br) (Schlag et al., 1998) and an
inhibitor of glutamate uptake, TNF- (Fine et al., 1996); the
cells were tested for EAAT1 and EAAT2 protein and RNA
expression 24 h after treatment. Protein and RNA inputs
were standardized by the levels of -tubulin and RPS,
respectively, and relative intensities of the bands were eval-
uated by densitometry. As shown in Fig. 7A, EAAT2 pro-
tein levels were clearly reduced after HIV-1 infection rela-
tive to untreated cells, but there was only a small reduction
in EAAT1 protein. In contrast, TNF- strongly inhibited the
expression of both proteins. As expected, 8-Br induced both
EAAT1 and EAAT2, although the two-fold induction of
EAAT2 was smaller than reported in studies using rat as-
trocytes (Schlag et al., 1998). The observed changes in
steady-state levels of EAAT1 and EAAT2 mRNA in HIV-1,
8-Br, or TNF--treated astrocytes (Fig. 7B) closely paral-
Fig. 4. HIV-1 infection of astrocytes monitored by p24 capsid antigen
production. Astrocytes were infected with cell-free NL4-3 at 1 IU per cell
and intracellular and extracellular viral capsid antigen p24 levels were
monitored over time after infection.
Fig. 3. Time course of L-[3H]-glutamate uptake in fetal astrocytes. Cell-
associated radiolabeled glutamate was measured at the indicated times as
described under Materials and methods. The activity of glutamate transport
inhibitors (inset) was assayed after 10 min of exposure and uptake.
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leled those seen at the protein level. Twenty-four hours after
HIV-1 infection there was a pronounced decline in the
primary transcript of EAAT2 relative to control RPS tran-
scripts. There was no visible effect of HIV-1 on EAAT1
RNA expression, consistent with its minimal effects upon
EAAT1 protein levels (Fig. 7A). Similar to induction of
Fig. 5. Inhibition of L-[3H]-glutamate uptake in fetal astrocytes by HIV-1 and gp120. Astrocytes were exposed to HIV-1 (A,C) or gp120 (B,D), and glutamate
uptake was evaluated as described under Materials and methods. The results shown are the means  SEM of duplicate or triplicate wells of % inhibition
relative to cells treated with medium in parallel. L-[3H]-glutamate assays were conducted for 10 min. (A) (B) The time course of the effects of virus and gp120
upon glutamate uptake was evaluated by testing astrocytes of 16 weeks gestational age at the indicated times after treatment with HIV-1 at 1 IU per cell (A)
or gp120 at 1 nM (B). (C) (D) The effects of HIV-1 (C) or gp120 (D) upon glutamate uptake were tested in multiple independent astrocyte populations 6
and 24 h after treatment as indicated. The data were pooled and plotted using the SigmaPlot statistical package for box plots. The line inside the box denotes
50%. The box extents denotes 75%; the capped bars denote 90%, and the dots flanking the box denote 95% of data values.
Fig. 6. HIV-1 reduces the Vmax for glutamate transport in fetal astrocytes. Fetal astrocytes were treated with medium (A) or infected by HIV-1 (B) and 24 h
later glutamate uptake assays were performed in the presence of increasing concentrations of unlabeled L-glutamate as described under Materials and methods.
Results are shown as the Eadie–Hofstee transformations of the concentration dependence of the high-affinity L-[3H]-glutamate transport in HIV-1-infected
fetal astrocytes and they represent the means  SEM of three independent experiments performed in triplicate. The Km and Vmax values are listed in the text.
Insets: Saturation kinetics of the same data in Michaelis–Menten plots.
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transporter proteins, 8-Br induced both EAAT1 and EAAT2
RNA and TNF- inhibited expression of EAAT1 and
EAAT2 (Fig. 7B). Similar to HIV-1-infected cells, astro-
cytes exposed to gp120MN for 24 h also showed significant
reduction in steady-state levels of EAAT2 protein and RNA
(Fig. 7C and D, respectively). No significant effect on
EAAT1 protein or RNA was seen in gp120-treated cells
(not shown). Comparable results were obtained in three
independent experiments using different pools of astrocytes.
Overall, our results indicate that HIV-1 and gp120 inhibit
EAAT2 gene transcription, resulting in reduced EAAT2
RNA and protein expression, reduced surface glutamate
transporters, and impaired uptake of glutamate. We also
show that TNF- inhibits the expression of both EAAT1
and EAAT2 at the RNA and protein levels, consistent with
its previously described effects upon glutamate uptake (Fine
et al., 1996).
HIV-1 infection or exposure to gp120 does not induce
secretion of TNF- by astrocytes
TNF- was shown to inhibit glutamate uptake in human
astrocytes (Fine et al., 1996) and as we show here, TNF-
inhibited the expression of both EAAT1 and EAAT2 pro-
tein and RNA in astrocytes (Fig. 7). Because exposure to
HIV-1 can induce TNF- synthesis by macrophages and
lymphocytes (Choe et al., 2001; Poli et al., 1990), we
investigated HIV-1 and gp120 as potential inducers of
TNF-. Fetal astrocytes were either infected with HIV-1 or
treated with gp120, or exposed to PMA or IL-1, known
inducers of NF-B and HIV-1 replication in astrocytes
(Shahabuddin et al., 1992b; Tornatore et al., 1991). In par-
allel, MDM serving as control were treated with PMA,
IL-1, or LPS, an activator of cytokine and chemokine
production in MDM (Choe et al., 2001), or exposed to
astrocyte supernatants, known to activate macrophages
(Nottet et. al., 1995). All the systems were tested for the
presence of TNF- in culture supernatants 24 h after treat-
ments (Fig. 8). The results clearly show that neither HIV-1
infection, nor gp120 exposure, nor any other treatments
used induced secretion of TNF- by human astrocytes. LPS
and PMA, but neither IL-1 nor astrocyte supernatant, in-
duced TNF- synthesis by MDM.
Discussion
Glutamate is the major neurotransmitter in the brain and
its removal from synapses by glutamate transporters is es-
sential for signal transmission and prevention of excitotoxic
Fig. 7. Inhibition of EAAT protein and RNA expression in fetal astrocytes after HIV-1 infection, exposure to gp120, or treatment with TNF- or
8-Br-c-cAMP. Fetal astrocytes of 18 weeks gestational age were infected with NL4-3 or treated with gp120, TNF-, or 8-Br. Six hours after treatment, cells
were harvested for protein and RNA extraction and detection by Western (A and C) or Northern (B and D) blot, respectively, as described under Materials
and methods. The intensities of protein and RNA bands were determined by densitometry as described; relative intensities are listed under the respective
bands.
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death of neurons (Anderson and Swanson, 2000; Choi,
1988; Danbolt, 2001; Gegelashvili and Schousboe, 1997).
Glutamate excitotoxicity has been proposed as part of the
etiology in several neurological diseases including amyo-
tropic lateral sclerosis, epilepsy, Alzheimer’s disease, as
well as HAD (Choi, 1988; Hansson et al., 2000; Kaul et al.,
2001; Maragakis and Rothstein, 2001). In the present work,
we demonstrate that exposure to HIV-1 or gp120 in culture
induces rapid, extensive, and lasting reduction of glutamate
transport by primary human astrocytes. Our data also indi-
cate that the proximal cause of this defect is transcriptional
downmodulation of the glial glutamate transporter EAAT2
and consequently EAAT2 protein. If astrocytes respond to
native HIV-1 or gp120 in vivo as we observe in vitro, this
virus-induced dysfunction may contribute to glutamate ex-
citotoxicity and neurodegeneration associated with HAD.
Several functional and molecular attributes of HIV-1 and
gp120 were investigated for their impact upon glutamate
uptake inhibition. We found that the inhibition of glutamate
uptake was extensive, reaching a peak of 70–90% at 6 h
(Fig. 5A). At 6 h, HIV-1-mediated glutamate uptake inhi-
bition averaged 76% and the gp120-mediated effect was
58%; 24 h after treatment inhibition was 54 and 36%,
respectively, at the optimal doses for each agent. Statistical
analysis of uptake results from up to 20 independent exper-
iments with tissues from different donors and with different
virus preparations (Fig. 5D) confirmed the generality and
extent of the virus and gp120 effects. Although uptake
results varied among individual experiments as indicated by
the data spreads shown in Fig. 5D, the observed inhibitory
trend was remarkably consistent across multiple experi-
ments, especially considering the expected differences in
genetic backgrounds of tissue donors and different gestation
times of the fetal tissue used. Glutamate uptake inhibition
was also observed during infection of feline astrocytes with
feline immunodeficiency virus (FIV) (Billaud et al., 2002;
Yu et al., 1998) and in human astrocytes cocultivated with
HTLV-I-infected T cells (Szymocha et al., 2000). FIV
causes an HAD-like disease in cats (Henriksen et al., 1995;
Pedersen and Barlough, 1991) that was shown to be accom-
panied by increased glutamate levels and neuronal loss in
the brain (Power et al., 1997) and HTLV-I is the etiologic
agent of tropical spastic paraparesis/HTLV-1-associated
myelopathy (Gessain et al., 1985; Osame et al., 1986),
suggesting that disruption of astrocyte glutamate transport
may be a common cytopathogenic activity of some neuro-
tropic retroviruses. In addition, Benos and colleagues
showed that treatment of rat astrocytes with exogenous
gp120 altered ion fluxes across the plasma membrane and
increased D-aspartate efflux (Benos et al., 1994a, b), while
Holden and colleagues demonstrated that gp120 can acti-
vate the Na/H exchangers, glutamate release, and [Ca2]
influx in human astrocytes (Holden et al., 1999), indicating
that exposure to gp120 alone can affect excitatory amino
acid transport in these cells.
The extent of HIV-1-mediated inhibition of glutamate
uptake in astrocytes, with a mean peak of 76%, indicated
that HIV-1 affected the great majority of cells in culture.
This was surprising considering that HIV-1 infection of
astrocytes is inefficient and generally fewer than 1% of the
cells have detectable HIV-1 antigens or DNA in experimen-
tal (Bagasra et al., 1992; Bencheikh et al., 1999; He et al.,
1997) or natural infection (Saito et al., 1994; Takahashi et
al., 1996; Tornatore et al., 1994a; Trillo-Pazos et al., 2003).
However, the finding that gp120 was comparable to infec-
tious HIV-1 in its inhibition of glutamate transport (Fig. 5)
indicates that the bulk of the inhibitory effects of HIV-1 can
be attributed to the virus interaction with cell surface, prior
to and independent of subsequent viral replication in the
minority of cells. Indeed, inactivation of HIV-1 replication
by irradiation did not affect its ability to inhibit glutamate
uptake by astrocytes (not shown). The time course of inhi-
bition also indicates its independence from virus replication:
glutamate uptake was inhibited as rapidly as 1 h after HIV-1
exposure (not shown) and reproducible and maximal inhi-
bition was observed at 6 h (Fig. 5A). The rapid kinetics of
HIV-1 and gp120 effects in human cells contrast with the
FIV system, in which inhibition of glutamate transport was
apparent only a week after infection and was more pro-
nounced with highly productive FIV/34TF10 than with the
low-productive FIV/PPR, indicating dependence on FIV
replication (Billaud et al., 2002; Yu et al., 1998). The
difference between the two systems may reflect the fact that
feline astrocytes are more permissive to FIV than are human
astrocytes permissive to HIV-1 (Fig. 4) (Billaud et al., 2002;
Tornatore et al., 1991, 1994a).
Analysis of changes in glutamate transport kinetics and
expression of transporters induced in response to HIV-1 or
gp120 (Figs. 6–8) permits us to draw some preliminary
conclusions concerning the mechanisms of the effect. Our
results suggest that the proximal cause of this inhibition is a
Fig. 8. TNF- is not induced by HIV-1 or gp120 treatment of fetal
astrocytes. Fetal astrocytes of 16 weeks gestational age or control MDM
were treated with the indicated agents and extracellular TNF- was as-
sayed by ELISA.
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reduction in the number of functional glutamate transport
sites on HIV-1-infected cells, as indicated by a 59% decline
in Vmax without change in Km (affinity) for glutamate (Fig.
6). The reduction in Vmax of glutamate transport correlated
directly with the decline in the steady-state levels of EAAT2
mRNA and protein, with EAAT1 expression less affected
(Fig. 7), indicating that HIV-1 and gp120 may act through
downmodulation of EAAT2. However, the glutamate up-
take assay employed here does not distinguish between
EAAT1 and EAAT2, and so we cannot yet conclude that the
observed marked decline in EAAT2 protein and RNA ac-
counts fully for the decline in glutamate transport function.
Studies are under way to distinguish between the activities
of the two transporters in glutamate uptake assays by means
of transporter-specific inhibitors and to determine the deg-
radation rates of EAAT1 and EAAT2 proteins and RNA.
The cellular pathways responsible for HIV-1-mediated
downmodulation of EAAT2 expression and glutamate
transport inhibition remain to be investigated. We tested
TNF- as one attractive candidate to transduce HIV-1 re-
sponse in astrocytes because HIV-1 can induce TNF-
synthesis in macrophages (Choe et al., 2001); exogenous
TNF- was shown to inhibit glutamate uptake through a
reduction in Vmax for glutamate transport (Fine et al., 1996),
and activation of endogenous TNF- by ligation of CXCR4
on astrocytes was reported to induce glutamate release
(Bezzi et al., 2001). However, no TNF- production was
observed in HIV-1 or gp120-treated astrocytes under con-
ditions where EAAT2 function and transcription were in-
hibited (Fig. 8). Moreover, the responses of astrocytes to
TNF- were markedly different from their responses to
HIV-1. TNF- required 24 h to achieve maximal inhibition
of glutamate uptake (Fine et al., 1996) and we report here
that it affected both EAAT1 and EAAT2 expression. HIV-1,
in contrast, achieved maximal inhibition 6 h after infection
and its effects were mediated mostly by changes in EAAT2
expression. Together, these experiments rule out TNF- as
the agent of inhibition of glutamate uptake induced by
HIV-1 and gp120 in this system.
Our results presented here and elsewhere (Su et al., 2002,
2003) indicate that HIV-1 and gp120 exposure alter the
transcriptional program of human astrocytes, resulting in
profound functional changes exemplified here by impaired
glutamate transport. Astrocytic maintenance of extracellular
glutamate within narrow limits is critical for glutamergic
signal transmission on the one hand and for preventing
overexcitation of glutamate receptors and neuronal cell
death on the other hand (Choi, 1988; Danbolt, 2001; Ma-
ragakis and Rothstein, 2001). Glutamate transport is tightly
regulated through transporter expression by astrocytes dur-
ing development, in the mature brain, and may be dysregu-
lated during disease (Choi, 1988; Danbolt, 2001; Maragakis
and Rothstein, 2001). Pathways of neuropathogenesis in-
volving factors ranging from TNF- and arachidonic acid to
amyloid precursor protein appear to functionally converge
in their disruption of glutamate transport in astrocytes,
thereby reducing glutamate clearance and, potentially, caus-
ing neurodegeneration (Dreyer and Lipton, 1995; Fine et al.,
1996; Li et al., 1997). Our data place HIV-1 and gp120 in
this category of the potentially pathogenic downmodulators
of glutamate transport in human astrocytes, suggesting that
the interaction of astrocytes with HIV-1 or gp120 may
directly contribute to glutamate excitotoxicity and neurode-
generation associated with HAD.
Materials and methods
Cells
Astrocytes were isolated from second trimester (14–19
weeks of gestational age) human fetal brains obtained from
elective abortions in full compliance with NIH guidelines,
as previously described (Bencheikh et al., 1999; Canki et
al., 2001). Homogenous preparations of astrocytes were
obtained using high-density culture conditions in the ab-
sence of growth factors in F12 Dulbecco’s modified Eagles
Medium (DMEM-F12) (GIBCO-Invitrogen, Carlsbad, CA)
containing 10% fetal bovine serum (FBS), penicillin, strep-
tomycin, and gentamycin. Cells were maintained in this
medium at 2–5  104 cells/cm2 and subcultured weekly up
to six times. Cultures were regularly monitored by immu-
nofluorescence staining for expression of the astrocytic
marker glial fibrillary acidic protein (GFAP) and HAM-56
to identify cells of the monocyte lineage. For these analyses,
cells were cultured on coverslips and stained and evaluated
as described (Canki et al., 2001), using primary antibodies
rabbit anti-GFAP and anti-HAM-56 (both from Dako Co.,
Carpinteria, CA), and anti-HLA DR (Roche Molecular Bio-
chemicals, Indianapolis, IN) and appropriate fluorochrome-
labeled secondary antibodies (Sigma, St. Louis, MO). Only
cultures that contained 99% GFAP-positive astrocytes
and no detectable HAM-56-positive cells were used in these
experiments (Fig. 1) and in Canki et al. (2001). Human
monocytes were isolated from peripheral blood mononu-
clear cells and differentiated to macrophages (MDM) for 7
days prior to use as described (Choe et al., 2001). Other
cells used in this study were the human embryonal kidney
epithelial cell line 293T, used for HIV-1 propagation, and
MAGI cells, a derivative of HeLa carrying the -gal gene
under the control of HIV-1 LTR and expressing HIV-1
receptors (Kimpton and Emerman, 1992), used as indicator
cells for HIV-1 titration. Both cell lines were cultured in
90% DMEM/10% FCS supplemented with antibiotics and,
for MAGI cells, 0.2 mg/ml G-418.
Viruses
The HIV-1 species primarily used in this work was
NL4-3, an X4 laboratory clone that expresses all known
HIV-1 proteins (Adachi et al., 1986). In some experiments,
a molecular clone of the X4 isolate NDK from Zaire (Spire
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et al., 1989) and a North American R5-isolate ADA (Gen-
delman et al., 1988) were used for comparison. Generally,
NL4-3 virus stocks were prepared by culture of infected
CEM cells; virus stocks were concentrated by high-speed
centrifugation (12,000 g, 2 h, 4°C), resuspended in PBS and
frozen at 80°C. Alternatively, NL4-3 and NDK were
propagated by transfection of 15 g of viral DNA into 1.5
 106 293T cells as previously described (Bencheikh et al.,
1999). Culture supernatants were harvested 72 h after trans-
fection, filtered through a 0.45-m Millipore filter, and
stored at80°C until use. ADA was propagated in MDM as
described (Choe et al., 2001). Cell-free viral stocks were
tested for HIV-1 p24 core antigen content by ELISA using
HIV-1 Ag kit according to the manufacturer’s instructions
(Coulter, Hialeah, FL), for titers of infectious virus by
MAGI assay (Kimpton and Emerman, 1992), and for the
presence of TNF- by Quantikine ELISA kit as described
below. Culture supernatants contained 1–2 g/ml of viral
p24 protein and 1–2  106 IU per milliliter but no detect-
able TNF-. NL4-3 virus preparations yielded similar re-
sults in astrocytes whether they were propagated in infected
CEM cells or transfected 293T cells.
HIV-1 infection or exposure to gp120
Early passage astrocytes were cultured for 5–7 days until
75% confluence; the cells were washed in warm PBS and
infected with HIV-1 at 1 IU per cell. Cell–virus mixtures
were incubated for 6 h; the cells were then washed three
times to remove input virus, cultured in fresh medium, and
harvested at time points indicated in the figures. Control
astrocytes were treated as described above but without
HIV-1. Cells were similarly treated with full-length, recom-
binant, glycosylated gp120MN protein (NIH AIDS Research
and Reagents Program, catalog no. 3927; produced by Im-
munoDiagnostic, Inc.) at a final concentration of 1 nM or
with control proteins at the concentrations indicated.
Progress of viral infection was monitored by measurement
of extracellular p24 in culture supernatant or intracellular
p24 by ELISA.
Glutamate uptake assays
Astrocytes were plated in triplicate at 1  105 cells per
well in 12-well tissue culture plates, grown for 6–8 days or
75% confluence, and equilibrated at 25°C in incubation
medium: 0.125 M NaCl, 4.5 mM KCl, 1.2 mM CaCl2, 1.2
mM MgCl2, and 5 mM glucose, buffered to pH 7.4 with
sodium phosphate. After addition of L-[3H]-glutamic acid
(DuPont NEN, Boston, MA; specific activity, 57.4 Ci/
mmol) at a final concentration of 1 M; cells were incu-
bated at 25°C for the designated time; the uptake was
terminated by washing cells twice in cold incubation me-
dium, and cells were solubilized overnight in 0.25 mM
NaOH. Cell-associated radioactivity was determined in cell
lysates by scintillation counting and total protein content in
lysates was determined by the Bio-Rad protein assay (Bio-
Rad, Hercules, CA). The results were expressed in nmoles
of L-[3H]-glutamate per milligram of cellular protein. To
determine the specificity of glutamate uptake, cells were
prepared for assay as described above and exposed to
L-[3H]-glutamate (1 M) alone or with an inhibitor of glu-
tamate transport L-trans-pyrrolidine-2,4-deoxycarbonate (L-
TPDC) (250 M), or substrate competitors L-aspartate (250
M) or L-glutamate (250 M). The uptake was terminated
after 10 min at 25°C as described above; the results are
shown in the inset in Fig. 3, expressed in nmol gluta-
mate/mg protein/min. To determine the kinetic constants of
glutamate uptake by astrocytes, cells were infected with
HIV-1 as described above or control cells were cultured for
24 h, washed, and tested in triplicate for L-[3H]-glutamate
uptake in the presence of 0.2–1000 M unlabeled L-gluta-
mate and 1 M L-[3H]-glutamate. Glutamate uptake was
determined after 10 min incubation. Data expressed as
pm/mg protein/min were plotted versus unlabeled glutamate
concentration. The Eadie–Hofstee transformation was used
to determine Vmax and Km using SigmaPlot 5.0 (SPSS, Inc.,
Chicago, IL).
Northern blot hybridization
Total cellular RNA from human fetal astrocytes was
extracted using Trizol. One microgram of RNAs per lane
was resolved on a 1.0% agarose/formaldehyde gel, trans-
ferred to a nylon membrane, and hybridized with an -32P-
labeled, DNA probe synthesized by PCR under standard
conditions. Briefly, the PCR reaction mixture contained 10
mM Tris–HCl pH 9.0, 50 mM KCl, 0.1% Triton X-100, 2
M each of dATP, dTTP, and dGTP, 033 M of
[-32P]dCTP, 2.0 mM MgCl2, 1 unit of Taq polymerase
(Promega), 50 ng of unlabeled PCR DNA fragment ob-
tained with the same pair of primers serving as a PCR
template, and 0.5 M of relevant primers in a total reaction
volume of 50 l. The cycling parameters were 1 min at
94°C, 1 min at 50°C, and 1 min 30 s at 72°C, and the
number of cycles was 35. The unincorporated dNTPs were
removed by spin column chromatography (Roche). Primers
for EAAT1 were as follows: (sense) 5-GCGCGGA-
TCCATGACTAAAAGCAATGGAGAAGAGCC-3; (anti-
sense) 5-CGCGCTCGAGTCTACATCTTGGTTTCACT-
GTCGATG-3. Primers for EAAT2 were as follows:
(sense) 5-GGGGGATCCCAGACCATGGCATCTAC-3
and (antisense) 5-GCTGGAATTCATATCCTTATTTCT-
CACG-3. The primers for small ribosomal RNA S9 (RPS),
used for standardization of total cellular RNA, were as
follows: (sense) 5-CCAGTGGCCCGGAGCTGGGTTT-
GTCG-3 and (antisense) 5-TCGTCGTCTCCAGC-
CCCAGCCCCACC-3. The hybridization was performed
in the ULTRAhyb (Ambion, Austin, TX) at 42°C overnight,
and the hybridized blots were washed twice with 2 SSC/
0.1% SDS, and then twice with 0.2 SSC/0.1% SDS at
42°C. The blots were autoradiographed by exposure to
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X-ray film. The relative levels of different RNAs were
quantified by densitometry, first by standardizing the OD
readings for a given system to their respective RPS signals,
and then expressing the standardized system value relative
to standardized untreated control (C) taken as 1.0.
Protein analysis by immunoblotting
Cells were lysed in a buffer containing 1% Triton X-100,
50 mM Tris–HCl, pH 7.8, 5 mM EDTA, 50 mM NaCl, 5
mM lodoacetamide, 0.1 mM phenylmethylsulfonyl fluoride,
0.1 mM leupeptin, and 14 M pepstatin; cell lysates were
standardized by total protein content, and 2–20 g protein/
lane were resolved by SDS–PAGE on 12% polyacrylamide
Ready Gels (Bio-Rad) and transferred onto a 0.2 m Trans-
Blot nitrocellulose membrane (Bio-Rad). The membranes
were incubated in 5% (w/v) skim milk in T-PBS (0.1%
polyoxyethyline-sorbitan monolaurate in phosphate-buff-
ered saline) and exposed to either monoclonal antibodies to
-tubulin (Sigma) or the previously described rabbit poly-
clonal antibodies to EAAT1 and EAAT2 (Bar-Peled et al.,
1997). Bound antibodies were detected by using appropriate
horseradish peroxidase conjugated secondary antibody
(Amersham, Piscataway, NJ), enhanced chemilumines-
cence, and autoradiography as previously described (Canki
et al., 2001). Total protein content in samples was verified
by their -tubulin content prior to final electrophoresis, and
the relative levels of proteins in different lanes were quan-
tified by densitometry as described for RNA analyses above.
Detection of TNF- in culture supernatants
TNF- in culture supernatants was measured using the
Quantikine ELISA kit (R&D Systems, Minneapolis, MN)
according to the manufacturer’s instructions. The following
control inducers were purchased: interleukin-1 (R&D Sys-
tems), lipopolysaccharide (LPS), and phorbol-12-myristate-
13-acetate (PMA) (Sigma).
Acknowledgments
This work is dedicated to the memory of Olga Pekar-
skaya. We thank G. Bentsman for excellent technical assis-
tance, I. Totillo for manuscript preparation, and M.J. Potash
for support, encouragement, and unwavering interest in the
working of the human CNS. We are grateful for the gifts of
reagents: HeLa-CD4-LTR--gal from M. Emerman, mono-
clonal anti-gp120 from B. Chesebro and K. Toohey, and
gp120 from ImmunoDiagnostics, Inc., all supplied through
the AIDS Research and Reference Reagent Program,
DAIDS, NIAID-NIH. This work was supported by Grant
P01 NS31492 from the National Institute of Neurological
Diseases and Stroke, NIH, PHS.
References
Adachi, A., Gendelman, H.E., Koenig, S., Folks, T., Willey, R., Rabson,
A., Martin, M.A., 1986. Production of acquired immunodeficiency
syndrome-associated retrovirus in human and nonhuman cells trans-
fected with an infectious molecular clone. J. Virol. 59, 284–291.
An, S.F., Groves, M., Giometto, B., Beckett, A.A.J., Scaravilli, F., 1999.
Detection and localisation of HIV-1 DNA and RNA in fixed adult
AIDS brain by polymerase chain reaction/in situ hybridisation tech-
nique. Acta Neuropathol. 98, 481–487.
Anderson, C.M., Swanson, R.A., 2000. Astrocyte glutamate transport:
review of properties, regulation, and physiological functions. Glia 32,
1–14.
Arriza, J.L., Fairman, W.A., Wadiche, J.I., Murdoch, G.H., Kavanaugh,
M.P., Amara, S.G., 1994. Functional comparisons of three glutamate
transporter subtypes cloned from human motor cortex. J. Neurosci. 14,
5559–5569.
Bagasra, O., Khalili, K., Seshamma, T., Taylor, P.J., Pomerantz, R.J.,
1992. TAR-independent replication of human immunodeficiency virus
type 1 in glial cells. J. Virol. 66, 7522–7528.
Bagasra, O., Lavi, E., Bobroski, L., Khalili, K., Pestaner, J.P., Tawadros,
R., Pomerantz, R.J., 1996. Cellular reservoirs of HIV-1 in the central
nervous system of infected individuals: identification by the combina-
tion of in situ polymerase chain reaction and immunohistochemistry.
AIDS 10, 573–585.
Bar-Peled, O., Ben-Hur, H., Biegon, A., Groner, Y., Dewhurst, S., Furuta,
A., Rothstein, J.D., 1997. Distribution of glutamate transporter sub-
types during human brain development. J. Neurochem. 69, 2571–2580.
Beattie, E.C., Stellwagen, D., Morishita, W., Bresnahan, J.C., Ha, B.K.,
Von Zastrow, M., Beattie, M.S., Malenka, R.C., 2002. Control of
synaptic strength by glial TNF. Science 295, 2282–2285.
Bencheikh, M., Bentsman, G., Sarkissian, N., Canki, M., Volsky, D.J.,
1999. Replication of different clones of human immunodeficiency virus
type 1 in primary fetal human astrocytes: enhancement of viral gene
expression by Nef. J. Neurovirol. 5, 115–124.
Benos, D.J., Hahn, B.H., Bubien, J.K., Ghosh, S.K., Mashburn, N.A.,
Chaikin, M.A., Shaw, G.M., Benveniste, E.N., 1994a. Envelope gly-
coprotein gp120 of human immunodeficiency virus type 1 alters ion
transport in astrocytes: implications for AIDS dementia complex. Proc.
Natl. Acad. Sci. USA 91, 494–498.
Benos, D.J., McPherson, S., Hahn, B.H., Chaikin, M.A., Benveniste, E.N.,
1994b. Cytokines and HIV envelope glycoprotein gp120 stimulate
Na/H exchange in astrocytes. J. Biol. Chem. 269, 13811–13816.
Bezzi, P., Domercq, M., Brambilla, L., Galli, R., Schols, D., De Clercq, E.,
Vescovi, A., Bagetta, G., Kollias, G., Meldolesi, J., Volterra, A., 2001.
CXCR4-activated astrocyte glutamate release via TNF: amplification
by microglia triggers neurotoxicity. Nat. Neurosci. 4, 702–710.
Billaud, J.N., Selway, D., Yu, N., Phillips, T.R., 2002. Replication rate of
feline immunodeficiency virus in astrocytes is envelope dependent:
implications for glutamate uptake. Virology 266, 180–188.
Brack-Werner, R., 1999. Astrocytes: HIV cellular reservoirs and important
participants in neuropathogenesis. AIDS 13, 1–22.
Brew, B.J., Rosenblum, M., Cronin, M., Price, R.W., 1995. AIDS dementia
complex and HIV-1 brain infection: clinical-virologic correlations.
Ann. Neurol. 38, 563–570.
Budka, H., 1991. Neuropathology of human immunodeficiency virus in-
fection. Brain Pathol. 1, 163–175.
Canki, M., Potash, M.J., Bentsman, G., Chao, W., Flynn, T., Heinemann,
M., Gelbard, H., Volsky, D.J., 1997. Isolation and long-term culture of
primary ocular human immunodeficiency virus type 1 isolates in pri-
mary astrocytes. J. Neurovirol. 3, 10–15.
Canki, M., Thai, J.N.F., Chao, W., Ghorpade, A., Potash, M.J., Volsky,
D.J., 2001. Highly productive infection with pseudotyped human im-
munodeficiency virus type 1 (HIV-1) indicates no intracellular restric-
tions to HIV-1 replication in primary human astrocytes. J. Virol. 75,
7925–7933.
70 Z. Wang et al. / Virology 312 (2003) 60–73
Cheng-Mayer, C., Rutka, J.E., Rosenblum, M.L., McHugh, T., Stites, D.P.,
Levy, J.A., 1987. Human immunodeficiency virus can productively
infect cultured human glial cells. Proc. Natl. Acad. Sci. USA 84,
3526–3530.
Choe, W., Volsky, D.J., Potash, M.J., 2001. Induction of rapid and exten-
sive -chemokine synthesis in macrophages by human immunodefi-
ciency virus type 1 and gp120, independently of their coreceptor
phenotype. J. Virol. 75, 10738–10745.
Choi, D.W., 1988. Glutamate neurotoxicity and diseases of the nervous
system. Neuron 1, 623–634.
Conant, K., Garzino-Demo, A., Nath, A., McArthur, J.C., Halliday, W.,
Power, C., Gallo, R.C., Major, E.O., 1998. Induction of monocyte
chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and ele-
vation in AIDS. Proc. Natl. Acad. Sci. USA 95, 3117–3121.
Danbolt, N.C., 2001. Glutamate uptake. Prog. Neurobiol. 65, 1–105.
Dewhurst, S., Sakai, K., Bresser, J., Stevenson, M., Evinger-Hodges, M.J.,
Volsky, D.J., 1987. Persistent productive infection of human glial cells
by human immunodeficiency virus (HIV) and by infectious molecular
clones of HIV. J. Virol. 61, 3774–3782.
Dong, Y., Benveniste, E.N., 2001. Immune function of astrocytes. Glia 36,
180–190.
Dreyer, E.B., Lipton, S.A., 1995. The coat protein gp120 of HIV-1 inhibits
astrocyte uptake of excitatory amino acids via macrophage arachidonic
acid. Eur. J. Neurosci. 7, 2502–2507.
Everall, I.P., Luthert, P.J., Lantos, P.L., 1991. Neuronal loss in the frontal
cortex in HIV infection. Lancet 337, 1119–1121.
Fine, S.M., Angel, R.A., Perry, S.W., Epstein, L.G., Rothstein, J.D., De-
whurst, S., Gelbard, H.A., 1996. Tumor necrosis factor  inhibits
glutamate uptake by primary human astrocytes. J. Biol. Chem. 271,
15303–15306.
Gegelashvili, G., Danbolt, N.C., Schousboe, A., 1997. Neuronal soluble
factors differentially regulate the expression of the GLT1 and GLAST
glutamate transporters in cultured astroglia. J. Neurochem. 69, 2612–
2615.
Gegelashvili, G., Schousboe, A., 1997. High affinity glutamate transport-
ers: regulation of expression and activity. Mol. Pharmacol. 52, 6–15.
Gendelman, H.E., Orenstein, J.M., Martin, M.A., Ferrua, C., Mitra, R.,
Phipps, T., Wahl, L.A., Lane, H.C., Fauci, A.S., Burke, D.S., Skillman,
D., Meltzer, M.S., 1988. Efficient isolation and propagation of human
immunodeficiency virus on recombinant colony-stimulating factor-1
treated monocytes. J. Exp. Med. 167, 1428–1441.
Gessain, A., Barin, F., Vernant, J.C., Gout, O., Maurs, L., Calender, A., de
The, G.,, 1985. Antibodies to human T-lymphotropic virus type-1 in
patients with tropical spastic paraparesis. Lancet ii, 407–410.
Glass, J.D., Fedor, H., Wesselingh, S.L., McArthur, J.C., 1995. Immuno-
cytochemical quantitation of human immunodeficiency virus in the
brain: correlations with dementia. Ann. Neurol. 38, 755–762.
Gosztonyi, G., Artigas, J., Lamperth, L., Webster, H.D., 1994. Human
immunodeficiency virus (HIV) distribution in HIV encephalitis: study
of 19 cases with combined use of in situ hybridization and immuno-
cytochemistry. J. Neuropathol. Exp. Neurol. 53 (5), 521–534.
Hansson, E., Muyderman, H., Leonova, J., Allansson, L., Sinclair, J.,
Blomstrand, F., Thorlin, T., Nilsson, M., Ro¨nnba¨ck, L., 2000. Astroglia
and glutamate in physiology and pathology: aspects on glutamate
transport, glutamate-induced cell swelling and gap-junction communi-
cation. Neurochem. Int. 37, 317–329.
Hatch, W.C., Pousada, E., Losev, L., Rashbaum, W.K., Lyman, W.D.,
1994. Neural cell targets of human immunodeficiency virus type 1 in
human fetal organotypic cultures. AIDS Res. Hum. Retroviruses 10,
1597–1607.
He, J., DeCastro, C.M., Vandenbark, G.R., Busciglio, J., Gabuzda, D.,
1997. Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit
protooncogene. Proc. Natl. Acad. Sci. USA 94, 3954–3959.
Henriksen, S.J., Prospero-Garcia, O., Phillips, T.R., Fox, H.S., Bloom,
F.E., Elder, J.H., 1995. Feline immunodeficiency virus as a model for
study of lentivirus infection of the central nervous system. Curr. Top.
Microbiol. Immunol. 202, 167–186.
Hery, C., Wingertsmann, L., Levy, Y., Gray, F., Tardieu, M., 1997. HIV-1
induces apoptosis in cultured human neurons and microglial cells but
not in astrocytes. Neuropathol. Appl. Neurobiol. 23, 352–353.
Holden, C.P., Haughey, N.J., Nath, A., Geiger, J.D., 1999. Role of Na/H
exchangers, excitatory amino acid receptors and voltage-operated Ca2
channels in human immunodeficiency virus type 1 gp120-mediated
increases in intracellular Ca2 in human neurons and astrocytes. Neu-
roscience 91 (4), 1369–1378.
Iino, M., Goto, K., Kakegawa, W., Okado, H., Sudo, M., Ishiuchi, S.,
Miwa, A., Takayasu, Y., Saito, I., Tsuzuki, K., Ozawa, S., 2001.
Glia-synapse interaction through Ca2 -permeable AMPA receptors in
Bergmann Glia. Science 292, 926–929.
Kaul, M., Garden, G.A., Lipton, S.A., 2001. Pathways to neuronal injury
and apoptosis in HIV-associated dementia. Nature 410, 988–994.
Kimpton, J., Emerman, M., 1992. Detection of replication-competent and
pseudotyped human immunodeficiency virus with a sensitive cell line
on the basis of activation of an integrated -galactosidase gene. J. Vi-
rol. 66, 2232–2239.
Koening, S., Gendelman, H., Orenstein, M.J., Canto, M.C., Pezeshkpour,
G.H., Yungbluth, G.H., Janotta, F., Aksamit, A., Martin, M.A., Fauci,
A.S., 1986. Detection of AIDS virus in macrophages in brain tissue
from AIDS patients. Science 233, 1089–1093.
Korber, B.T.M., Kunstman, K.J., Patterson, B.K., Furtado, M., McEvilly,
M.M., Levy, R., Wolinsky, S.M., 1994. Genetic differences between
blood- and brain-derived viral sequences from human immunodefi-
ciency virus type 1-infected patients: evidence of conserved elements
in the V3 region of the envelope protein of brain-derived sequences.
J. Virol. 68, 7467–7481.
Krajewski, S., James, H.J., Ross, J., Blumberg, B.M., Epstein, L.G., Gen-
delman, H.E., Gummuluru, S., Dewhurst, S., Sharer, L.R., Reed, J.C.,
Gelbard, H.A., 1997. Expression of pro- and anti-apoptosis gene prod-
ucts in brains from pediatric patients with HIV-1 encephalitis. Neuro-
pathol. Appl. Neurobiol. 23, 242–253.
Kunsch, C., Hartle, H.T., Wigdahl, B., 1989. Infection of human fetal
dorsal root ganglion glial cells with human immunodeficiency virus
type 1 involves an entry mechanism independent of the CD4 T4A
epitope. J. Virol. 63, 5054–5061.
Li, S., Mallory, M., Alford, M., Tanaka, S., Masliah, E., 1997. Glutamate
transporter alterations in Alzheimer disease are possibly associated
with abnormal APP expression. J. Neuropathol. Exp. Neurol. 56, 901–
911.
Lipton, S., Gendelman, H.E., 1995. Dementia associated with the acquired
immunodeficiency syndrome. New Engl. J. Med. 233, 934–940.
Ma, M., Geiger, J.D., Nath, A., 1994. Characterization of a novel binding
site for the human immunodeficiency virus type 1 envelope protein
gp120 on human fetal astrocytes. J. Virol. 68, 6824–6828.
Maragakis, N.J., Rothstein, J.D., 2001. Glutamate transporters in neuro-
logic disease. Arch. Neurol. 58, 365–370.
Nath, A., Hartloper, V., Furer, M., Fowke, K.R., 1995. Infection of human
fetal astrocytes with HIV-1: viral tropism and the role of cell to cell
contact in viral transmission. J. Neuropathol. Exp. Neurol. 54, 320–
330.
Navia, B.A., Cho, E.S., Petito, C.K., Price, R.W., 1986. The AIDS demen-
tia complex: II. Neuropathology. Ann. Neurol. 19, 525–535.
Navia, B.A., Jordan, B.D., Price, R.W., 1986. The AIDS dementia com-
plex: I. Clinical features. Ann. Neurol. 19, 517–524.
Navia, B.A., Price, R.W., 1987. The acquired immunodeficiency syndrome
dementia complex as the presenting or sole manifestation of human
immunodeficiency virus type infection. Arch. Neurol. 44, 65–69.
Nottet, H.S.L.M., Jett, M., Flanagan, C.R., Zhai, Q.-H., Persidsky, Y.,
Rizzino, A., Bernton, E.W., Genis, P., Baldwin, T., Schwartz, J.H.,
LaBenz, C.J., Gendelman, H.E., 1995. A regulatory role for astrocytes
in HIV-1 encephalitis. J. Immunol. 154, 3567–3581.
Nuovo, G.J., Gallery, F., MacConnell, P., Braun, A., 1994. In situ detection
of polymerase chain reaction-amplified HIV-1 nucleic acid and tumor
necrosis-alpha RNA in the central nervous system. Am. J. Pathol. 144,
659–666.
71Z. Wang et al. / Virology 312 (2003) 60–73
Ohagen, A., Ghosh, S., He, J., Huang, K., Chen, Y., Yuan, M., Osath-
anondh, R., Gartner, S., Shi, B., Shaw, G., Gabuzda, D., 1999.
Apoptosis induced by infection of primary brain cultures with diverse
human immunodeficiency virus type 1 isolates: evidence for a role of
the envelope. J. Virol. 73, 897–906.
Oliet, S.H.R., Piet, R., Poulain, D.A., 2001. Control of glutamate clearance
and synaptic efficacy by glial coverage of neurons. Science 292, 923–
926.
Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A.,
Matsumoto, M., Tara, M., 1986. HTLV-1 associated myelopathy, a
new clinical entity. Lancet i, 1031–1032.
Palacin, M., Este´vez, R., Bertran, J., Zorzano, A., 1998. Molecular biology
of mammalian plasma membrane amino acid transporters. Physiol.
Rev. 78, 969–1054.
Pedersen, N.C., Barlough, J.E., 1991. Clinical overview of the feline
immunodeficiency virus. J. Am. Vet. Med. Ass. 199, 1298–1315.
Persidsky, Y., Limoges, J., McComb, R., Bock, P., Baldwin, T., Tyor, W.,
Patil, A., Nottet, H.S., Epstein, L., Gelbard, H., Flanagan, E., Reinhard,
J., Pirruccello, S.J., Gendelman, H.E., 1996. Human immunodeficiency
virus encephalitis in SCID mice. Am. J. Pathol. 149, 1027–1053.
Poli, G., Kinter, A., Justement, J.S., Kehrl, J.H., Bressler, P., Stanley, S.,
Fauci, A.S., 1990. Tumor necrosis factor  functions in an autocrine
manner in the induction of human immunodeficiency virus expression.
Proc. Natl. Acad. Sci. USA 87, 782–785.
Power, C., McArthur, J.C., Johnson, R.T., Griffin, D.E., Glass, J.D., Per-
ryman, S., Chesebro, B., 1994. Demented and nondemented patients
with AIDS differ in brain-derived human immunodeficiency virus type
1 envelope sequences. J. Virol. 68, 4643–4649.
Power, C., McArthur, J.C., Nath, A., Wehrly, K., Mayne, M., Nishio, J.,
Langelier, T., Johnson, R.T., Chesebro, B., 1998. Neuronal death in-
duced by brain-derived human immunodeficiency virus type 1 enve-
lope genes differs between demented and nondemented AIDS patients.
J. Virol. 72, 9045–9053.
Power, C., Moench, T., Peeling, J., Kong, P.-A., Langelier, T., 1997. Feline
immunodeficiency virus causes increased glutamate uptake levels and
neuronal loss in brain. Neuroscience 77, 1175–1185.
Ranki, A., Nyberg, M., Ovod, V., Haltia, M., Elovaara, I., Raininko, R.,
Haapasolo, H., Krohn, K., 1995. Abundant expression of HIV Nef and
Rev proteins in brain astrocytes in vivo is associated with dementia.
AIDS 9, 1001–1008.
Robinson, M.B., 1998. Examination of glutamate transporter heterogeneity
using synaptosomal preparations, in: Amara, S.G. (Ed.), Methods in
Enzymology. Neurotransmitter Transporters, Vol. 296. Academic
Press, Portland, OR, pp. 189–202.
Robinson, M.B., 1999. The family of sodium-dependent glutamate trans-
porters: a focus on the GLT-1/EAAT2 subtype. Neurochem. Int. 33,
479–491.
Rosenberg, Z.F., Fauci, A.S., 1989. Induction of expression of HIV in
latently or chronically infected cells. AIDS Res. Hum. Retroviruses 5,
1–4.
Sabri, F., Tresoldi, E., Di Stefano, M., Polo, S., Monaco, M.C., Verani, A.,
Fiore, R.J., Lusso, P., Major, E., Chiodi, F., Scarlatti, G., 1999. Non-
productive human immunodeficiency virus type 1 infection of human
fetal astrocytes: independence from CD4 and major chemokine recep-
tors. Virol. 264, 370–384.
Sacktor, N., Lyles, R.H., Skolasky, R., Kleeberger, C., Selnes, O.A.,
Miller, E.N., Becker, J.T., Cohen, B., McArthur, J.C., 2001. HIV-
associated neurologic disease incidence changes: Multicenter AIDS
Cohort Study, 1990–1998. Neurology 56, 257–260.
Saito, Y., Sharer, L.R., Epstein, L.G., Michaels, J., Mintz, M., Louder,
M., Golding, K., Cvetkovich, T.A., Blumberg, B.M., 1994. Over-
expression of Nef as a marker for restricted HIV-1 infection of
astrocytes in postmortem pediatric central nervous tissues. Neurol-
ogy 44, 474 – 481.
Schlag, B.D., Vondrasek, J.R., Munir, M., Kalandadze, A., Zelenaia, O.A.,
Rothstein, J.D., Robinson, M.B., 1998. Regulation of the glial Na-
dependent glutamate transporters by cyclic AMP analogs and neurons.
Mol. Pharmacol. 53, 355–369.
Shahabuddin, M., Volsky, B., Hsu, M.C., Volsky, D.J., 1992a. Restoration
of cell surface CD4 expression in human immunodeficiency virus type
1-infected cells by treatment with a Tat antagonist. J. Virol. 66, 6802–
6805.
Shahabuddin, M., Volsky, B., Kim, H., Sakai, K., Volsky, D.J., 1992b.
Regulated expression of human immunodeficiency virus type 1 in
human glial cells: induction of dormant virus. Pathobiology 60, 195–
205.
Sharer, L.R., Epstein, L.G., Cho, E.S., Joshi, V.V., Meyenhofer, M.F.,
Rankin, L.F., Petito, C.K., 1986. Pathologic features of AIDS enceph-
alopathy in children: evidence for LAV/HTLV-III infection of brain.
Hum. Pathol. 17, 271–284.
Shi, B., De Girolami, U., He, J., Wang, S., Lorenzo, A., Busciglio, J.,
Gabuzda, D., 1996. Apoptosis induced by HIV-1 infection of the
central nervous system. J. Clin. Invest. 98, 1979–1990.
Shibata, T., Yamada, K., Watanabe, M., Ikenaka, K., Wada, K., Tanaka,
K., Inoue, Y., 1997. Glutamate transporter GLAST is expressed in the
radial glia-astrocyte lineage of developing mouse spinal cord. J. Neu-
rosci. 17, 9212–9219.
Smit, T.K., Wang, B., Ng, T., Osborne, R., Brew, B., Saksena, N.K., 2001.
Varied tropism of HIV-1 isolates derived from different regions of
adult brain cortex discriminate between patients with and without
AIDS dementia complex (ADC): evidence for neurotropic HIV vari-
ants. Virology 279, 509–526.
Spire, B., Sire, J., Zachar, V., Rey, F., Barre-Sinoussi, F., Galibert, F.,
Hampe, A., Chermann, J.C., 1989. Nucleotide sequence of HIV-1-
NDK: a highly cytopathic strain of the human immunodeficiency virus.
Gene 81, 275–284.
Stoler, M.H., Eskin, T.A., Benn, S., Angerer, R.C., Angerer, L.M., 1986.
Human T-cell lymphotropic virus type III infection of the central
nervous system. A preliminary in situ analysis. JAMA 256 (17), 2360–
2364.
Su, Z.-z., Kang, D.-c., Chen, Y., Pekarskaya, O., Chao, W., Volsky, D.J.,
Fisher, P.B., 2002. Identification and cloning of human astrocyte genes
displaying elevated expression after infection with HIV-1 or exposure
to HIV-1 envelope glycoprotein by rapid subtraction hybridization,
RaSH. Oncogene 21, 3592–3602.
Su, Z.-z., Kang, D.-c., Chen, Y., Pekarskaya, O., Chao, W., Volsky, D.J.,
Fisher, P.B., 2003. Identification of gene products suppressed by HIV-1
infection or gp120 exposure of primary human astrocytes by rapid
subtraction hybridization. J. NeuroVirol. 00, 000–000.
Szymocha, R., Akaoka, H., Dutuit, M., Malcus, C., Didier-Bazes, M.,
Belin, M.-F., Giraudon, P., 2000. Human T-cell lymphotropic virus
type 1-infected T lymphocytes impair catabolism and uptake of gluta-
mate by astrocytes via Tax-1 and tumor necrosis factor alpha. J. Virol.
74, 6433–6441.
Takahashi, K., Wesselingh, S.L., Griffin, D.E., McArthur, J.C., Johnson,
R.T., Glass, J.D., 1996. Localization of HIV-1 in human brain using
polymerase chain reaction/in situ hybridization and immunocytochem-
istry. Ann. Neurol. 39, 705–711.
Thompson, K.A., McArthur, J.C., Wesselingh, S.L., 2001. Correlation
between neurological progression and astrocyte apoptosis in HIV-
associated dementia. Ann. Neurol. 49, 745–752.
Tornatore, C., Chandra, R., Berger, J.R., Major, E.O., 1994a. HIV-1 in-
fection of subcortical astrocytes in the pediatric CNS. Neurology 44,
481–487.
Tornatore, C., Meyers, K., Atwood, W., Conant, K., Major, E.O., 1994b.
Temporal patterns of human immunodeficiency virus type 1 transcripts
in human fetal astrocytes. J. Virol. 68, 93–102.
Tornatore, C., Nath, A., Amemiya, K., Major, E.O., 1991. Persistent
human immunodeficiency virus type 1 infection in human fetal glial
cells reactivated by T-cell factor(s) or by the cytokines tumor
necrosis factor alpha and interleukin-1 beta. J. Virol. 65, 6094 –
6100.
72 Z. Wang et al. / Virology 312 (2003) 60–73
Trillo-Pazos, G., Diamanturos, A., Rislove, L., Menza, T., Chao, W.,
Belem, P.S.S., Morgello, S., Sharer, L., Volsky, D.J., 2003. Detec-
tion of HIV-1 DNA in microglia/macrophages, astrocytes and neu-
rons isolated from brain tissue with HIV-1 encephalitis by laser
capture microdissection. Brain Pathol. 13, 145–154.
Ullian, E.M., Sapperstein, S.K., Christopherson, K.S., Barres, B.A., 2001.
Control of synapse number by glia. Science 291, 657–660.
Verkhratsky, A., Orkand, R.K., Kettenmann, H.B., 1998. Glial calcium:
homeostasis and signaling function. Physiol. Rev. 78, 100–130.
Wiley, C.A., 1996. Polymerase chain reaction in situ hybridization-opening
pandora’s box. Ann. Neurol. 39, 691–692.
Wiley, C.A., Schrier, R.D., Nelson, J.A., Lampert, P.W., Oldstone,
M.B.A., 1986. Cellular localization of human immunodefi-
ciency virus infection within the brains of acquired immune defi-
ciency syndrome patients. Proc. Natl. Acad. Sci. USA 83, 7089 –
7093.
Ye, Z.-C., Rothstein, J.D., Sontheimer, H., 1999. Compromised glutamate
transport in human glioma cells: reduction-mislocalization of sodium-
dependent glutamate transporters and enhanced activity of cystine-
glutamate exchange. J. Neurosci. 19, 10767–10777.
Yu, N., Billaud, J.N., Phillips, T.R., 1998. Effects of feline immunodeficiency virus
on astrocyte glutamate uptake: implications for lentivirus-induced central ner-
vous system diseases. Proc. Natl. Acad. Sci. USA 95, 2624–2629.
Zheng, J., Ghoparde, A., Niemann, D., Cotter, R.L., Thylin, M.R., Epstein,
L., Swartz, J.M., Shepard, R.B., Liu, X., Nukuna, A., Gendelman, H.E.,
1999. Lymphotropic virions affect chemokine receptor-mediated neu-
ral signaling and apoptosis: implications for human immunodeficiency
virus type 1-associated dementia. J. Virol. 73, 8256–8267.
73Z. Wang et al. / Virology 312 (2003) 60–73
